回答: 继续 由 博论百战穿金甲 于 2020-04-22 2:07

REFERENCES
1. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a
treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob
Agents 2020:105949. doi: 10.1016/j.ijantimicag.2020.105949
2. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID19:
results of a randomized clinical trial. medRxiv 2020:2020.03.22.20040758.
3. Jun C, Danping L, Li L, et al. A pilot study of hydroxychloroquine in treatment of
patients with common coronavirus disease-19 (COVID-19).
J Zhejiang Univ (Med Sci) 2020. doi: 10.3785/j.issn.1008-9292.2020.03.03
4. Mahevas M, Tran V-T, Roumier M, et al. No evidence of clinical efficacy of
hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement:
results of a study using routinely collected data to emulate a target trial. medRxiv
2020:2020.04.10.20060699.
5. Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or
clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with
severe COVID-19 infection. Médecine et Maladies Infectieuses 2020. doi:
10.1016/j.medmal.2020.03.006
6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for
Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020. doi:10.1001/jama.2020.6019
7. Voss A. Official Statement from International Society of Antimicrobial Chemotherapy
(ISAC). 2020. https://www.isac.world/news-and-publications/isac-elsevier-statement
8. Rome BN, Avorn J. Drug Evaluation during the Covid-19 Pandemic. N Engl J Med 2020.
doi: 10.1056/NEJMp2009457
9. Food and Drug Administration. 2020. (Accessed 15 Apr, 2020, at
https://www.fda.gov/media/136537/download)
10. Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
China. N Engl J Med 2020. doi: 10.1056/NEJMoa2002032
11. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet
2020;395:1054-62.
12. Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses
for competing risk data. Stat Med 2017;36:4391-400.
13. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing
Risk. Journal of the American Statistical Association 1999;94:496-509.
14. Liu M, Lu W, Shao Y. A Monte Carlo approach for change-point detection in the Cox
proportional hazards model. Stat Med 2008;27:3894-909.
15. Sfumato P, Boher J-M. CRAN-Package goffte: Goodness-of-Fit for Time-to-Event Data.
R package version 1.0.5, ed2017.
16. Tian Y, Baro E, Zhang R. Performance evaluation of regression splines for propensity
score adjustment in post-market safety analysis with multiple treatments. Journal of
Biopharmaceutical Statistics 2019;29:810-21.
17. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is
effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16.